GL1X · GenesisL1 explorer

Research workbench

Crystal structure of 14-3-3 epsilon with 9J10 peptide

Analyse Crystal structure of 14-3-3 epsilon with 9J10 peptide in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7C8E
Type
protein
Length
473 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
14-3-3 protein epsilon; 9J10
UniProt
P62258
Pockets
6 · best druggability 0.54

Structure

x-ray diffraction · 3 distinct chains · 78% helix, 0% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, B14-3-3 protein epsilonprotein23082% helix, 0% strandP62258
C9J10protein60% helix, 0% strand—
D9J10protein70% helix, 0% strand—

Ligands and binding sites

  • TRS · 2-amino-2-hydroxymethyl-propane-1,3-diol · additive · chains B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

6 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13380.540.7428empty
21280.520.8021empty
31170.450.7819empty
4970.450.7914empty
5890.440.7916empty

Interfaces

3 interfaces between chains.

  • A–B · 1041 Ų buried · 9 hydrogen bonds · protein-protein
  • A–C · 587 Ų buried · 18 hydrogen bonds · protein-protein
  • B–D · 539 Ų buried · 21 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 modified (phosphorylation).

Compared structures

  • 7C8E · Crystal Structure of 14-3-3 epsilon with 9J10 peptide · the same entry in another collection · chain A against A, TM-score 1.00
  • P62258 · AlphaFold monomer V2.0 prediction for 14-3-3 protein epsilon (P62258) · a predicted model of the same protein · chain B against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.